Edinburgh-based biotech company Ingenza Ltd. has made a significant breakthrough in the race to develop and manufacture a cost-effective vaccine against SARS-CoV-2, the virus responsible for the current COVID-19 pandemic. Ingenza has been working closely with researchers at Oxford University and the UK CPI, Wilton, since the start of the outbreak, and the collaboration is
The post Ingenza meets a key milestone in the deployment of novel cost-effective COVID-19 vaccine technology appeared first on Pharma Mirror Magazine.
